长非编码RNAH19通过H19/miR-107/CDK6轴促进肝细胞癌细胞的增殖
Archittapon Nokkeaw1,2,3, Pannathon Thamjamrassri1,2,3, Naphat Chantaravisoot1,4
1Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Oncology research
|September 25, 2023
概括
肝细胞癌 (HCC) 的进展是由长非编码RNA H19.19驱动的. H19 作为 miR-107 的分子海绵,促进 CDK6 表达和细胞增殖,这表明 H19 抑制是潜在的 HCC 治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因规则 基因规则
背景情况:
- 肝细胞癌 (HCC) 是全球主要的癌症,治疗选择有限.
- 了解HCC分子机制对于开发新疗法至关重要.
- 包括H19在内的长非编码RNA (lncRNAs) 涉及HCC,但H19的作用尚不清楚.
研究的目的:
- 阐明H19在肝细胞癌中的生物功能.
- 研究H19影响HCC细胞生长和进展的分子机制.
- 根据H19法规,确定基于HCC的潜在治疗点.
主要方法:
- 在HCC细胞系中抑制和过度表达H19.
- 细胞周期分析 (G1-S阶段过渡) 和亡试验.
- 对细胞循环调节剂 (如CDK6.6) 的基因表达分析 (RNA和蛋白质)
- 生物信息分析和双 luciferase 记者测定证实了 H19,miR-107 和 CDK6.6 之间的相互作用.
主要成果:
- H19 knockdown 抑制了 HCC 细胞生长,细胞周期进展受损,并诱导了亡.
- H19过度表达产生了相反的效果.
- 抑制H19导致CDK6表达的减少.
- H19与miR-107直接相互作用,作为一种海绵,抑制miR-107的活性并促进CDK6的表达.
结论:
- H19通过海绵化miR-107促进HCC细胞增殖,导致CDK6表达和细胞周期进展的增加.
- H19在驱动HCC的过程中起着关键的机械作用.
- 抑制H19代表了一种有前途的新疗法策略,用于治疗HCC.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Formation of Muscle Fibers from Myoblasts
5.0K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
5.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


